Treat-and-resect Study of Echo Decorrelation Imaging-controlled Radiofrequency Ablation in Liver Tumors

Inclusion Criteria:

1. Age ≥18 years.
2. Scheduled for resection of at least one confirmed primary or metastatic liver tumor with estimated diameter \<5 cm at the University of Cincinnati Medical Center (UCMC).
3. Patients may have other disease (typically cirrhosis, hepatitis B or hepatitis C) for primary liver cancer patients and extrahepatic cancer (typically colorectal) for metastatic liver cancer patients.
4. Ability to understand and the willingness to sign the written research informed consent document for this study.

Exclusion Criteria:

1. The tumor for which the resection is scheduled is greater than or equal to 5 cm in diameter.
2. The tumor for which the resection is scheduled has received: prior ablation; chemoembolization; or, other treatment which in the opinion of the PI would disqualify a patient from participation.
3. Radiofrequency ablation (RFA) is contra-indicated for safety reasons in the opinion of the PI and/or clinical treatment team according to current standards of care (e.g., tumor adjacent to the heart, bowel, gall bladder, or bile ducts; impaired liver function; implanted cardiac devices).
4. Proceduralist assessment that research-specific radiofrequency ablation or intraoperative ultrasound imaging would cause substantial patient risk.
5. Pregnant women, prisoners, institutionalized individuals, or other individuals from vulnerable populations.
6. Patients who are receiving any other investigational agents. Patients who have received other investigational agents previously who are no longer receiving these investigational agents may be eligible at the discretion of the PI.